Clinical Trials Monitor

Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
David B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 25; DOI: 10.1186/s40425-016-0130-4
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg, Naiyer A. Rizvi

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 48; DOI: 10.1186/s40425-016-0153-x
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Hasan Rehman, Ann W. Silk, Michael P. Kane, Howard L. Kaufman

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 53; DOI: 10.1186/s40425-016-0158-5
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang, Sandra Demaria, Silvia Formenti

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 51; DOI: 10.1186/s40425-016-0156-7
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 23; DOI: 10.1186/s40425-018-0335-9
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 35; DOI: 10.1186/s40425-018-0342-x
Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results
Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki, Andrzej Mackiewicz

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 134; DOI: 10.1186/s40425-018-0456-1

Main menu

Clinical Trials Monitor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical Trials Monitor

Pages